TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02510612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Dexmedetomidine(D) group, patient will be given dexmedetomidine 1μg/Kg for 10 minutes In anesthesia maintenance, D group will be given dexmedetomidine 0.4μg/Kg.h until 40 minutes before the end of surgery
Study: NCT04075461

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal fixation
Description: Internal fixation is commonly used for undisplaced femoral neck fracture
Study: NCT02807545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scoliosis Specific Exercises
Study: NCT04185246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NH002 (Perflutren Lipid Microspheres) Injectable Suspension
Description: NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.
Study: NCT01935934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01175993

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elliptical exercise
Description: Each participant with TBI will participate in an exercise intervention which will be done in the home. The exercise device in this protocol will be an elliptical trainer that requires coordinated reciprocal movements of both the legs and the arms. Primary emphasis will be placed on maintaining a near maximal speed of movement and to progressively increase this over time. Mild resistance to the leg motion will be provided initially and will be progressively increased once speed and coordination are optimized. The device will be loaned to them to use in the home, and will be delivered to the home fully assembled. Participants will be monitored by phone the first week and thereafter every two weeks and progressed as indicated. The exercise program will be performed 5 days a week for 30 minutes per session, for a total duration of 12 weeks. All will record the length, speed and resistance of each session on a paper-based log sheet.
Study: NCT03626220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi's Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, Limited., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi's Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, Limited., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints
Study: NCT03801876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Undergo esophagectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Undergo esophagectomy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Folinic acid, flurouracil and oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Folinic acid, flurouracil and oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX regimen
Description: Capecitabine combined with oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX regimen
Description: Capecitabine combined with oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU
Description: Chemotherapy
Study: NCT05620797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate loading of the implants
Description: Patients of this group will be rehabilitated by implant-retained mandibular overdenture with immediate loading of the implants as opposed to conventional maxillary complete dentures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed loading of the implant
Description: Patients of this group will be rehabilitated by implant retained mandibular overdenture with delayed loading of the implants (after 3 months) opposed by conventional maxillary complete dentures
Study: NCT02510612

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
Study: NCT00972283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
Study: NCT02235129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breath-holding
Study: NCT04577794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970
Description: GLPG3970 powder and solvent for oral solution reconstituted prior to use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder and solvent for oral solution reconstituted prior to use.
Study: NCT03182790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instant Messaging IM
Description: Smokers can communicate with counsellors in real-time through instant messaging (social media). Our counsellors will trigger the conversation and invite the smokers to response after initial contact. Counsellors will keep contact with the smokers to offer help, positive encouragement, reflections and reminders about SC according to smokers' personal needs and to encourage them to seek SC services. Details of successfully booked SC appointment (e.g. SC services address, contact information, date, appointment number etc.) will be delivered to the smokers using IM. All smokers will receive a reminder-to-attend IM messages 1-3 days before the appointment date.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular messages
Description: Regular messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent to smokers after initial contact via social media.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD advice
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral card
Description: The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief advice
Description: Very brief, minimal and general smoking cessation advice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COSH booklet
Description: A general smoking cessation self-help booklet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COSH booklet
Description: A general smoking cessation self-help booklet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo Messages
Description: Placebo messages will be sent via smart phones (e.g. social media) to remind subjects to take follow-up calls before each follow-up time points.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warning Leaflet
Description: The leaflet will include the information about the health risks of smoking.
Study: NCT02166359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extraneal (Icodextrin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose solution
Study: NCT01944748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Able To Resolve Situations (FARS)
Description: Family mediation is a method of resolving conflicts between parents and teens. During the mediation session, the parent and teen each meet one-on-one with a trained volunteer mediator, who is a neutral person who listens to each party's concerns without taking sides. Then the parent and teen come together and meet with this mediator to work on resolving conflicts they are having. Families participate in up to 3 mediation sessions.
Study: NCT02465164

Intervention type: DEVICE
Group type: OTHER
Intervention: Cook catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study: NCT02324361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The Fitbit Zip is a wireless physical activity monitor that will be worn by the index child during waking hours, and will be used to assess daily active time for the duration of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The Fitbit Zip is a wireless physical activity monitor that will be worn by the index child during waking hours, and will be used to assess daily active time for the duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence-based information on healthy family routines
Description: Educational dimensions include nutrition, frequency of family meals, child's screen time, bedtime routines, physical activity, and sleep hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence-based information on healthy family routines
Description: Educational dimensions include nutrition, frequency of family meals, child's screen time, bedtime routines, physical activity, and sleep hours.
Study: NCT05651386

Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: No blinded, no controlled intervention.
Study: NCT01948921

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Study: NCT02568462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
Description: Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
Study: NCT00490516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-104
Description: 200 mg, tablet, BID, 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-104
Description: 100 mg, tablet, BID, 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, tablet BID, 6 weeks
Study: NCT03313778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-4157
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-4157
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-4157
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-4157
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-4157
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-4157
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-4157
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-4157
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study: NCT01189877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eppendorf hypoximeter
Description: Patients consented to the protocol will proceed to their surgery date without any change in the standard preoperative period. After arriving in the operating room, the patient will undergo intravenous general anesthesia (or spinal/epidural anesthesia) by the anesthesiologist and will receive 40% oxygen. At this time, the principal investigator (along with the assistance of the operating surgeon and a member of the Department of Medical Physics) will use the Eppendorf hypoximeter to gather pO2 measurements. We anticipate that this will add no more than fifteen minutes to the planned procedure. Once the measurements are collected, the anesthesia will be adjusted as appropriate for the surgery and the procedure will continue as usual.
Study: NCT02390089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin vapor
Description: Single-breath and continuous inhalation paradigm to induce cough.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin vapor
Description: Single-breath and continuous inhalation paradigm to induce cough.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin vapor
Description: Single-breath and continuous inhalation paradigm to induce cough.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fog
Description: Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fog
Description: Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic swallow evaluation
Description: Fluoroscopic evaluation of oropharyngeal swallowing function.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic swallow evaluation
Description: Fluoroscopic evaluation of oropharyngeal swallowing function.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nebulizer
Description: A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulizer
Description: A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulizer
Description: A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.
Study: NCT01454011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosteron 250mg injection
Description: The combination of 4 different testosterone esthers (30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate) injected in 3 weeks intervals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone 50mg transdermal application
Description: Application of testosterone 50mg transdermal gel in every night
Study: NCT02638987

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
Study: NCT02256813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K1
Study: NCT03513263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and polishing
Description: An electronic scaler will be used to clean the gums

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral hygiene instructions
Description: It will include 15-minute oral session with visual and verbal information on how to use a toothbrush, dental floss, and mouthwash correctly; how to clean bridges and dentures; and how and why to use a plaque disclosing test to perform tooth cleaning

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: oral hygiene instructions
Description: It will include 15-minute oral session with visual and verbal information on how to use a toothbrush, dental floss, and mouthwash correctly; how to clean bridges and dentures; and how and why to use a plaque disclosing test to perform tooth cleaning
Study: NCT03442647

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: sinistrin clearance dynamic measurement
Description: sinistrin clearance measurements will be performed before and 90 min after oral protein load

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: sinistrin clearance dynamic measurement
Description: sinistrin clearance measurements will be performed before and 90 min after oral protein load

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: sinistrin clearance dynamic measurement
Description: sinistrin clearance measurements will be performed before and 90 min after oral protein load
Study: NCT03653845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular chemical Ablation of Adrenal Gland
Description: Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequenced antihypertensvie drugs with titrated dosage
Description: Patients will be treated with different antihypertensive drugs in two groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequenced antihypertensvie drugs with titrated dosage
Description: Patients will be treated with different antihypertensive drugs in two groups.
Study: NCT04143191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib is one of tyrosine kinase inhibitors. The initial dosage is 400mg orally, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib is one of tyrosine kinase inhibitors. The initial dosage is 400mg orally, twice daily.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization
Description: TACE including conventional TACE (cTACE) and DEB-TACE. Treatment choices are according to the specific condition of each patient and the experience of interventional radiologists.